Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterised by a dysregulated inflammatory response. Severe cases of IBD are treated with infliximab or adalimumab (anti-tumour necrosis factor (TNF)), which are therapeutic
antibodies targeting the pro-inflammatory cytokine TNF-α. They block the binding of TNF-α to its cell-surface receptors and limit downstream cell signalling pathways . The efficacy of anti-TNF treatment has been established in clinical trials. These studies of carefully selected patients found that anti-TNF treatment was efficient [1-3]. The efficacy of such treatment in every-day clinical practice is less well established [4-10]. An evaluation of the outcome of anti-TNF treatment in clinical practice is needed to shape the future role of anti-TNF treatment . Moreover, clinical trials suggest that approximately one-third of the patients do not respond to anti-TNF treatment . Tools which may help the clinicians to identify those patients who are most likely to benefit from anti-TNF treatment are warranted.
The aims of the present study were twofold. First, we wanted to evaluate the outcome of anti-TNF treatment in a cohort of patients from clinical practice. Next, we wanted to establish a cohort for future studies on genetic variation associated with treatment response. Therefore, we established a clinically based cohort
of previously naïve anti-TNF treated Danish patients with IBD from the 18 largest medical departments in Denmark.
Prior to anti-TNF therapy, routine screening for Mycobacterium tuberculosis infection was performed as the treatment may lead to activation of latent infection. Therefore, we collected the unique personal identification number of Danish citizens (the CPR number) from all patients who had a blood sample analysed for M. tuberculosis at Statens Serum Institut (SSI, Copenhagen, Denmark) from 01.09.2009 to 30.03.2011 and at the Department of Respiratory Diseases B and the Department of Clinical Microbiology, Aarhus University Hospital (Aarhus, Denmark) from 01.01.2011 to 30.03.2011. The CPR numbers were linked to The National Patient Registry, and we examined 1,378 patient records from patients with ICD-10 codes of K50-K63, which included intestinal diseases, from 18 medical departments.
Database design and contents
In order to facilitate data acquisition, ensure data quality, and enable centralisation of data storage, a secure web-based database was constructed by Datamanagement (Datamanagement, Aarhus, Denmark).
Data were collected retrospectively from patient records. Data included information on disease (CD or UC), gender, year of birth, age at diagnosis, CD location and behaviour and UC distribution according to the Montreal classification, smoking status, the date of the first anti-TNF treatment (infliximab (Remicade; Centocor, Malvern, PA, USA) or adalimumab (Humira; Abbott Laboratories, North Chicago, IL, USA)), treatment indication, C-reactive protein (CRP), faecal-calprotectin (F-cal) and treatment efficacy (as described later). Furthermore, concomitant medication with azathioprine or methotrexate for up to 4 weeks and 5-aminosalicylates, intravenous or peroral glucocorticoids or antibiotics up to two weeks before the first infliximab or adalimumab treatment were registered.
Finally, operation codes KJF, KJG and KGH were extracted.
Indication for treatment was: Patients with moderate or severe disease who did not respond to prednisolone or immunosuppressive treatment. Patients were routinely treated with 5 mg/kg infliximab intravenously starting at week 0, 2, 6 and every eight weeks thereafter. As a standard, adalimumab was administered with 160 mg subcutaneously in week 0, 80 mg in week 2, and 40 mg every second week thereafter [12, 13].
The 3-step scale used in previous studies was used to estimate efficacy eight and 22 weeks after anti-TNF treatment initiation in naïve patients and reflected the maximum response during the period [4-6, 11]. Patients with CD or UC with luminal disease were categorised as having: (A) no response, meaning no improvement or worsening of symptoms; (B) partial response, meaning some improvement of symptoms or reduction of steroid dose without worsening of symptoms; (C) response, meaning absence or almost absence of all clinical symptoms without increasing the steroid dose. Patients with fistulising CD were categorised as having: (A) no response, meaning no improvement or worsening of symptoms; (B) partial response, meaning reduced secretion or discomfort from fistulas or closure of one or some of the fistulas; (C) response, meaning closure of all fistulas evaluated by thumb pressure or no secretion.
A chi-square test or unpaired t-test was used to test if there was a statistically significant difference in response between patients with CD and UC and to examine if there was a difference in secondary parameters between responders and non-responders. Statistical analyses were performed using STATA version 11 (STATA Corp., Texas, USA).
The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Regional Ethical Committees (M20100153 and S-20120113) and the Danish Data Protection Agency (J. 2010-41-4719). The Local Regional Ethical Committees gave suspension for obtaining written informed consent.
Trial registration: Clinicaltrials NCT02322008.
Identification of cases
During the inclusion period, 10,425 blood samples from 9,217 individuals were collected as shown in Figure 1. From the medical departments, 1,519 patients had ICD-10 codes of K50-K63 and 1,378 (91%) patient records from 18 hospitals were examined. Among the examined 1,378 patient records, 1,095 patients with IBD were identified of whom 808 previously anti-TNF naïve patients were treated with infliximab or adalimumab. Forty-nine patients had to be excluded due to missing data.
Data on efficacy were available for 759 patients and included 535 (70%) responders, 94 (12%) partial responders and 130 (17%) non-responders (Table 1). The response rate was 65% (173 patients) and 74% (362 patients) among patients with UC and CD, respectively (odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.48-0.91, p = 0.01). The non-response rate was 24% (63 patients) and 14% (67 patients) among patients with UC and CD, respectively (OR = 1.96, 95% CI: 1.34-2.87, p = 0.001). Among patients with CD, the response rate to infliximab and adalimumab treatment was 74% (302 patients) and 70% (60 patients), respectively (p = 0.12). The rate of non-response was 17% (48 patients) and 9% (19 patients) among females and males with CD, respectively (OR = 2.07, 95% CI: 1.13-3.81, p = 0.02).
Clinical markers associated with response
Heavy smoking was associated with a low response rate among patients with CD with 18% (12 patients) of the non-responders versus 9% (31 patients) of the responders smoking ten or more cigarettes per day (OR = 2.33, 95% CI: 1.13-4.81, p = 0.03) (Table 1).
Young age at treatment initiation was associated with a beneficial response among patients with CD, with a median age of 33 (13-80) and 40 (16-75) years among responders and non-responders, respectively (p = 0.03).
A high pre-treatment CRP level (CRP ≥ 20 mg/l, twice the upper limit of the normal range) or a high pre-treatment faecal-calprotectin level (faecal-calprotectin > 200 mg/kg) were not associated with anti-TNF response. However, a decrease in CRP or faecal-calprotectin level by ≥ 25% within 22 weeks after treatment initiation was associated with a beneficial response (OR = 3.93, 95% CI: 1.91-8.10, p < 0.01 and OR = 25, 95% CI: 2.52-248.19, p < 0.01, respectively).
CD location, UC distribution, treatment indication (flare-up, fistula or side effects to other medications), concomitant medication (azathioprine, 5-aminosalicylates, glucocorticoids, methotrexate or antibiotics) or overall smoking status were not associated with treatment response.
As shown in Table 2, 76 (10%) of the 759 patients treated with infliximab or adalimumab terminated the treatment because of adverse events. Treatment termination due to adverse events occurred in 10% and 9% of the patients with CD and UC, respectively, and in 9% and 11% of responders and non-responders, respectively.
The most severe adverse events were one case of serum sickness, one anaphylactic reaction and one case of cardiac failure. No deaths were reported.
Five partial responders with UC and 5 patients with CD and 23 patients with UC, who were non-responders, were colectomised within 22 weeks of treatment initiation. Four patients with UC who initially responded to anti-TNF therapy lost the effect and were colectomised within 22 weeks of treatment initiation.
Anti-TNF response was assessed in a clinically based cohort of 759 previously anti-TNF naïve Danish IBD patients sampled from 18 medical departments. Response was evaluated as the maximum response within 22 weeks of treatment initiation. We found that anti-TNF treatment of patients with CD and UC was effective with response rates of 74% and 65%, respectively. The response rate in our retrospective study may be slightly higher than in other studies due to the exclusion of 49 patients, many of whom may have been non-responders. Furthermore, we found a significantly higher rate of non-response among patients with UC than among patients with CD. Heavy smoking was associated with non-response, whereas young age at treatment initiation was associated with a beneficial treatment response among patients with CD.
The main result of the present study is that we achieved similar results in clinical practice as have been obtained in clinical trials with carefully selected patients [1-3]. Our results from the present large cohort support the previous findings of a high primary response rate in clinically based cohort studies [4-10]. Additionally, our findings of higher rates of non-response among patients with UC, among female patients with CD and among patients with CD smoking 10 or more cigarettes per day are in accordance with the results of previous, smaller studies [14, 15]. In addition, our findings that young age at treatment initiation was associated with a beneficial response among patients with CD and that a decrease of 25% or more of pre-treatment CRP or faecal-calprotectin levels was associated with a beneficial response are in accordance with the results of other studies [14, 16, 17]. The use of azathioprine and methotrexate has been associated with a beneficial response after short-term treatment and fewer infusion reactions among patients with CD and UC treated with anti-TNF [6, 14, 15]. We were unable to confirm this result, probably because of lack of power. The incidence of adverse events was in line with that reported in previous studies (Table 2) [1, 2]. Among patients with CD with fistulising disease, the response rate in our retrospective study, reflecting the best response within 22 weeks, was similar to the response rates reported in other prospective and retrospective studies [4-6, 11].
All in all, we found similar anti-TNF treatment results in this clinically based cohort as have been found in clinical trials and in the few previously published clinically based studies. The results indicate that this cohort may be used for future studies on genetic variation associated with treatment response [18-20]. Identification of clinically useful markers that may predict treatment response will help the clinician to stratify and thus select patients who will respond to anti-TNF therapy and to avoid treatment of patients who will not respond. Until now, biomarkers are used mainly in oncology for personalised therapy. Furthermore, knowledge on the underlying biological mechanisms may lead to the development of new, better targeted therapies.
The present study was a large nationwide Danish multicentre study of patients in clinical practice, including 759 previously anti-TNF naïve IBD patients. However, data were collected retrospectively and were not available for all patients, which prevented the calculation of a score, such as the Harvey-Bradshaw Index (HBI) or the Simple Clinical Colitis Activity Index (SCCAI), for determination of treatment response. Instead, the response was the best response within 22 weeks based on the physician’s global assessment which has also been used in other retrospective studies. In the light of the obtained p-values and the number of statistical tests performed, we cannot exclude that our positive findings may be due to chance. Nor can we exclude that associations were not identified due to insufficient power.
This clinically based cohort of Danish patients treated with anti-TNF found high response rates. Heavy smoking was associated with non-response, whereas young age at treatment initiation was associated with beneficial treatment response among patients with CD. Thus, our clinical experiences were in line with results obtained from clinical trials.
Correspondence: Steffen Bank, Medical Department, Viborg Regional Hospital, 8800 Viborg. E-mail: email@example.com
Accepted: 8 January 2015
Conflicts of interest:Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk
Acknowledgements: We thank Morten Frydenberg, Department of Biostatistics, University of Aarhus, Denmark, and Hans Jacob Rud Christensen, Data Management, Aarhus, Denmark, for advice and assistance and the staff at the Library at Viborg Regional Hospital for valuable help.
Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;
Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-7.
Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-25.
Oussalah A, Evesque L, Laharie D et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;
Armuzzi A, Pugliese D, Danese S et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013;19:1065-72.
Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000;
Danese S, Colombel JF, Peyrin-Biroulet L et al. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther 2013;37:855-66.
Dignass A, Van AG, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28-62.
Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 2003;17:1451-7.
Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002;123:707-13.
Vermeire S, Louis E, Carbonez A et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol 2002;97:2357-63.
Schreiber S, Reinisch W, Colombel JF et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis 2013;7:213-21.
Bank S, Nexo BA, Andersen V et al. High-quality and -quantity DNA extraction from frozen archival blood clots for genotyping of single-nucleotide polymorphisms. Genet Test Mol Biomarkers 2013;17:501-3.
Bank S, Andersen PS, Burisch J et al. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogen J 2014:1-9.
Bank S, Andersen PS, Burisch J et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS One 2014;9:e98815.